Brian N. Bundy

University of South Florida — United States

Medicine · Health Sciences

67h-index33.4kcitations167works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Endometrial and Cervical Cancer Treatments(52), Ovarian cancer diagnosis and treatment(47), Diabetes and associated disorders(35), Diabetes Management and Research(33), Pancreatic function and diabetes(29)

Publications161 total

68-OR: Influence of the Type 1 Diabetes Genetic Risk Score on Response to Immunotherapies for Type 1 Diabetes Prevention
Diabetes·2024
Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials
2024Open Access
Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials
Diabetes Care·2024· 6 citedOpen Access
Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials
2024Open Access
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
Journal of Clinical Oncology·2023· 119 cited
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial
2023Open Access
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial
Diabetes Care·2023· 87 citedOpen Access
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial
2023Open Access
Correction to: Episodic Ataxia Type 1: Natural History and Effect on Quality of Life
The Cerebellum·2022· 1 citedOpen Access
Index60 Is Superior to HbA1c for Identifying Individuals at High Risk for Type 1 Diabetes
The Journal of Clinical Endocrinology & Metabolism·2022· 7 citedOpen Access
Episodic Ataxia Type 1: Natural History and Effect on Quality of Life
The Cerebellum·2022· 1 citedOpen Access
Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts
Diabetes Care·2021· 11 citedOpen Access
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
The Lancet Diabetes & Endocrinology·2021· 123 citedOpen Access
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
Science Translational Medicine·2021· 331 citedOpen Access
Imatinib Therapy for Patients with Recent-Onset Type 1 Diabetes: A Randomised Blinded Phase 2 Trial
SSRN Electronic Journal·2021· 2 citedOpen Access
Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes
Diabetes Technology & Therapeutics·2020· 70 citedOpen Access
The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis
The Journal of Clinical Endocrinology & Metabolism·2020· 7 citedOpen Access
277-OR: Teplizumab Reverses the Loss of C-Peptide in Relatives at Risk for Type 1 Diabetes (T1D)
Diabetes·2020· 3 cited
C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet
Diabetes Care·2020· 67 citedOpen Access
A quantitative measure of treatment response in recent‐onset type 1 diabetes
Endocrinology Diabetes & Metabolism·2020· 22 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Jeffrey P. Krischer(15), Carla J. Greenbaum(15), Jay S. Skyler(14), Stephen E. Gitelman(13), Peter A. Gottlieb(13), Desmond Schatz(13), Linda A. DiMeglio(12), Jennifer B. Marks(12), Antoinette Moran(12), Diane K. Wherrett(10), Darrell M. Wilson(10), William T. Creasman(9), Kevan C. Herold(9), Robin Goland(9), Philip Raskin(9), Henry Rodriguez(8), William E. Russell(8), Dorothy J. Becker(8), Howard D. Homesley(7), Frederick B. Stehman(7)